Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
delamanid + optimized background regimen
- Development stage
- Unknown
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
delamanid + optimized background regimen is a combination therapy used for the treatment of multidrug-resistant tuberculosis (MDR-TB). Delamanid (Deltyba), developed by Otsuka Pharmaceutical, is a bicyclic nitroimidazooxazole small molecule that acts as a prodrug, activated by the bacterial enzyme deazaflavin-dependent nitroreductase (Ddn). Once activated, it inhibits the synthesis of methoxy-mycolic and keto-mycolic acids, which are essential components of the Mycobacterium tuberculosis cell wall. The optimized background regimen (OBR) refers to a personalized combination of other anti-tuberculosis drugs, such as fluoroquinolones and second-line injectables, selected based on the patient's specific drug resistance profile and World Health Organization (WHO) guidelines. This combination is approved for use in both adult and pediatric patients with pulmonary MDR-TB when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.
- Brand names
- Deltyba
- Other names
- delamanid plus OBROPC-67683 + OBR
02
Targets
KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on delamanid + optimized background regimen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on delamanid + optimized background regimen.